Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine and sufentanil during mechanical thrombectomy under general anesthesia
ChiCTR2000028795Phase 4Not yet recruiting
- Sponsor
- Yidu Central Hospital of Weifang City
- Start
- Jan 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dexmedetomidine and sufentanil in ischemic stroke and atherothrombotic stroke (3 arms), sponsored by Yidu Central Hospital of Weifang City. Primary endpoints: Total nimodipine consumption within 48 hours after operation, Blood pressure and 2 more. Planned start Jan 2020; status: not yet recruiting.
02
Drugs
dexmedetomidinesufentanil
03
Conditions
ischemic strokeatherothrombotic stroke
Beyond the preview
Go deeper on ChiCTR2000028795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000028795.